Literature DB >> 3843591

Factors discriminating survivors and nonsurvivors in alcoholic heart disease.

M Kino, Y Nakayama, M Hara, S Yamamoto, K Sawada, T Saitoh, M Suwa, Y Hirota, Y Kitaura, K Kawamura.   

Abstract

Eighteen patients with dilated cardiomyopathy and a history of excessive ethanol intake were monitored for 3-98 months (mean 23 months). Six patients died (mean age 43.7 +/- 9.2 years) and 12 patients survived (mean age 48.8 +/- 9.5 years). Of the echocardiographic findings taken during heart failure, only the relative wall thickness to the internal dimension of the left ventricle (t/r ratio) differed significantly (survivors 0.33 +/- 0.77 vs. nonsurvivors 0.25 +/- 0.04, P less than 0.05). Of the hemodynamic data obtained after treatment of heart failure, left ventricular end-diastolic pressure differed significantly (survivors 6 +/- 2 vs. nonsurvivors 12 +/- 4 mmHg, P less than 0.001). The two groups could not be differentiated by ejection fraction, cardiac output, end-diastolic or end-systolic volumes, or semi-quantitative analysis of histologic findings obtained by right ventricular endomyocardial biopsy (light microscopy). Only two of six nonsurvivors (33%) succeeded in abstaining from alcohol, while eight of twelve survivors (67%) became teetotalers (P less than 0.05). Total abstinence from alcohol seems to be essential but was not necessarily followed by recovery in the most severe cases. Thus, the absence of adequate hypertrophy and high left ventricular filling pressure may predict the prognosis in alcoholic heart disease.

Entities:  

Mesh:

Year:  1985        PMID: 3843591     DOI: 10.1007/bf02072415

Source DB:  PubMed          Journal:  Heart Vessels Suppl        ISSN: 0935-736X


  24 in total

1.  ALCOHOLIC HEART DISEASE.

Authors:  W BRIGDEN; J ROBINSON
Journal:  Br Med J       Date:  1964-11-21

2.  Effects of chronic ethanol consumption on the myocardial hypertrophic response to a pressure overload in the rat.

Authors:  V Whitman; H G Schuler; J Musselman
Journal:  J Mol Cell Cardiol       Date:  1980-05       Impact factor: 5.000

3.  The natural history of idiopathic dilated cardiomyopathy.

Authors:  V Fuster; B J Gersh; E R Giuliani; A J Tajik; R O Brandenburg; R L Frye
Journal:  Am J Cardiol       Date:  1981-03       Impact factor: 2.778

4.  Report of the Joint International Society and Federation of Cardiology /World Health Organization Task Force on Recommendations for Standardization of Measurements from M-mode Echocardiograms.

Authors:  R A O'Rourke; P Hanrath; W N Henry; P G Hugenholtz; Z Pisa; J Roelandt; M Tanaka
Journal:  Circulation       Date:  1984-04       Impact factor: 29.690

5.  Variable prognosis in congestive cardiomyopathy. Role of left ventricular function, alcoholism, and pulmonary thrombosis.

Authors:  T Koide; A Kato; Y Takabatake; M Iizuka; Y Uchida; K Ozeki; S Morooka; M Makihana; T Serizawa; S Tanaka; T Ohya; S Momomura; S Murao
Journal:  Jpn Heart J       Date:  1980-07

6.  Left ventricular end-systolic stress-shortening and stress-length relations in human. Normal values and sensitivity to inotropic state.

Authors:  K M Borow; L H Green; W Grossman; E Braunwald
Journal:  Am J Cardiol       Date:  1982-12       Impact factor: 2.778

Review 7.  Left ventricular radius to wall thickness ratio.

Authors:  W H Gaasch
Journal:  Am J Cardiol       Date:  1979-06       Impact factor: 2.778

8.  Cardiac hypertrophy: useful adaptation or pathologic process?

Authors:  W Grossman
Journal:  Am J Med       Date:  1980-10       Impact factor: 4.965

9.  Factors influencing the one-year mortality of dilated cardiomyopathy.

Authors:  D V Unverferth; R D Magorien; M L Moeschberger; P B Baker; J K Fetters; C V Leier
Journal:  Am J Cardiol       Date:  1984-07-01       Impact factor: 2.778

10.  Determinants of survival in patients with congestive cardiomyopathy: quantitative morphologic findings and left ventricular hemodynamics.

Authors:  F Schwarz; G Mall; H Zebe; E Schmitzer; J Manthey; H Scheurlen; W Kübler
Journal:  Circulation       Date:  1984-12       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.